Cuba develops vaccine against lung cancer replacing chemo and radio.


Representation of the trisaccharide structure of a NeuGcGM3 ganglioside and its expression in tumor cells.

Representation of the trisaccharide structure of a NeuGcGM3 ganglioside and its expression in tumor cells.

“The most recent is RACOTUMOMAB (VAXIRA), and was approved in 2012 for use by today Center for State Control of drugs, equipment, and medical devices (CEDMED).(CUBA)

Administered intradermally, this does not cause the unpleasant side effects of chemotherapy and radiotherapy, which allows to make long-lasting treatments in elderly patients, who when they have a pulmonary carcinoma sometimes are not eligible to receive cytostatic.

Its security makes it easy to apply it to the primary health care level, called to be the future scenario of the therapeutic action against cancer, if finally the scientific advances come true the dream of turning it

into a disease that can live long in acceptable physical conditions.”

The Idiotypic Network hypothesis The Idiotypic Network hypothesis

 Racotumomab acts as a surrogate antigen Thus, when administered intradermally, Racotumomab acts as a surrogate antigen and activates the immune system to generate a specific response against tumor cells expressing the NeuGcGM3 ganglioside on their surface.

Simplified model showing the mechanism of action of Vaxira®

Source:http://www.granma.cu/ciencia/2014-11-07/el-reto-de-convertirlo-en-enfermedad-cronica

Argentina source:http://www.vaxira.com/eng/vaxira.php

ClinicalTrials.gov

A service of the U.S. National Institutes of Health
http://www.clinicaltrials.gov/show/NCT01460472
Anuncios

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s


A %d blogueros les gusta esto: